119 related articles for article (PubMed ID: 15755972)
1. Selective estrogen-receptor modulators for primary prevention of breast cancer.
Fabian CJ; Kimler BF
J Clin Oncol; 2005 Mar; 23(8):1644-55. PubMed ID: 15755972
[No Abstract] [Full Text] [Related]
2. Resistance to Resilience: Understanding Post-surgical Hormone Therapy in Breast Cancer Care.
Kumar T; Dutta RR; Thakre S; Singh A; Velagala VR; Shinde RK
Cureus; 2023 Oct; 15(10):e47869. PubMed ID: 38021507
[TBL] [Abstract][Full Text] [Related]
3. Adrenal Steroids and Resistance to Hormonal Blockade of Prostate and Breast Cancer.
Michael P; Roversi G; Brown K; Sharifi N
Endocrinology; 2023 Jan; 164(3):. PubMed ID: 36580423
[TBL] [Abstract][Full Text] [Related]
4. JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells.
Das P; Gupta A; Desai KV
Front Endocrinol (Lausanne); 2022; 13():1028616. PubMed ID: 36419768
[TBL] [Abstract][Full Text] [Related]
5. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection.
Allegretti M; Cesta MC; Zippoli M; Beccari A; Talarico C; Mantelli F; Bucci EM; Scorzolini L; Nicastri E
Cell Death Differ; 2022 Jan; 29(1):156-166. PubMed ID: 34404919
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis.
Shen YT; Huang X; Zhang G; Jiang B; Li CJ; Wu ZS
Front Oncol; 2021; 11():636365. PubMed ID: 34322374
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases.
Panossian AG; Efferth T; Shikov AN; Pozharitskaya ON; Kuchta K; Mukherjee PK; Banerjee S; Heinrich M; Wu W; Guo DA; Wagner H
Med Res Rev; 2021 Jan; 41(1):630-703. PubMed ID: 33103257
[TBL] [Abstract][Full Text] [Related]
8. Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory.
AlOmeir O; Patel N; Donyai P
Support Care Cancer; 2020 Nov; 28(11):5075-5084. PubMed ID: 32601852
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship.
Bodai BI; Nakata TE
Perm J; 2020; 24():. PubMed ID: 32589577
[TBL] [Abstract][Full Text] [Related]
10. Soy Food Consumption, Exercise, and Body Mass Index and Osteoporotic Fracture Risk Among Breast Cancer Survivors: The Shanghai Breast Cancer Survival Study.
Zheng N; Hsieh E; Cai H; Shi L; Gu K; Zheng Y; Bao PP; Shu XO
JNCI Cancer Spectr; 2019 Jun; 3(2):pkz017. PubMed ID: 31157323
[TBL] [Abstract][Full Text] [Related]
11. Eco-Friendly Formulated Zinc Oxide Nanoparticles: Induction of Cell Cycle Arrest and Apoptosis in the MCF-7 Cancer Cell Line.
Boroumand Moghaddam A; Moniri M; Azizi S; Abdul Rahim R; Bin Ariff A; Navaderi M; Mohamad R
Genes (Basel); 2017 Oct; 8(10):. PubMed ID: 29053567
[TBL] [Abstract][Full Text] [Related]
12. WW domain-binding protein 2: an adaptor protein closely linked to the development of breast cancer.
Chen S; Wang H; Huang YF; Li ML; Cheng JH; Hu P; Lu CH; Zhang Y; Liu N; Tzeng CM; Zhang ZM
Mol Cancer; 2017 Jul; 16(1):128. PubMed ID: 28724435
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.
Fabian CJ; Kimler BF; Zalles CM; Phillips TA; Metheny T; Petroff BK; Havighurst TC; Kim K; Bailey HH; Heckman-Stoddard BM
Cancer Prev Res (Phila); 2015 Dec; 8(12):1146-55. PubMed ID: 26391916
[TBL] [Abstract][Full Text] [Related]
14. Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors.
Das N; Baumgartner RN; Riley EC; Pinkston CM; Yang D; Baumgartner KB
J Cancer Surviv; 2015 Sep; 9(3):422-30. PubMed ID: 25913877
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.
Bodai BI; Tuso P
Perm J; 2015; 19(2):48-79. PubMed ID: 25902343
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene induces autophagy-dependent cell death in breast cancer cells via the activation of AMP-activated protein kinase.
Kim DE; Kim Y; Cho DH; Jeong SY; Kim SB; Suh N; Lee JS; Choi EK; Koh JY; Hwang JJ; Kim CS
Mol Cells; 2015; 38(2):138-44. PubMed ID: 25537862
[TBL] [Abstract][Full Text] [Related]
17. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo.
Wei W; Chen ZJ; Zhang KS; Yang XL; Wu YM; Chen XH; Huang HB; Liu HL; Cai SH; Du J; Wang HS
Cell Death Dis; 2014 Oct; 5(10):e1428. PubMed ID: 25275589
[TBL] [Abstract][Full Text] [Related]
18. Synergy and Antagonism of Active Constituents of ADAPT-232 on Transcriptional Level of Metabolic Regulation of Isolated Neuroglial Cells.
Panossian A; Hamm R; Kadioglu O; Wikman G; Efferth T
Front Neurosci; 2013; 7():16. PubMed ID: 23430930
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor testing and 10-year mortality from breast cancer: A model for determining testing strategy.
Naugler C
J Pathol Inform; 2012; 3():19. PubMed ID: 22616031
[TBL] [Abstract][Full Text] [Related]
20. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women.
Fourkala EO; Zaikin A; Burnell M; Gentry-Maharaj A; Ford J; Gunu R; Soromani C; Hasenbrink G; Jacobs I; Dawnay A; Widschwendter M; Lichtenberg-Fraté H; Menon U
Endocr Relat Cancer; 2012 Apr; 19(2):137-47. PubMed ID: 22199143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
